Although association between the missense variants of the NTRK genes and the development of malignant tumors has not been elucidated, it has been reported that if a tumor has the missense variants of the NTRK genes involving the kinase region, it becomes resistant to TRK inhibitors, larotrectinib, and entrectinib. Here, NTRK1 is linked to neoplasm.